BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, today announces that it has appointed Dr Michael Kauffman, M.D., Ph.D. to its Board of Directors as an Independent Non-Executive Director with immediate effect.

Dr Kauffman joins the BiVictriX Board with more than 20 years of experience in the life sciences industry, including expertise in preclinical research, clinical development, and regulatory strategy. He currently serves on the Boards of Karyopharm Therapeutics Inc (“Karyopharm”), Verastem Oncology, Kezar Life Sciences and Adicet Bio. After co-founding Karyopharm, Dr Kauffman served as Chief Executive Officer for over a decade, during which time he guided the company from a discovery stage biotechnology company to a commercial stage organisation and, most recently, transitioned into the role of Senior Clinical Advisor. Prior to joining Karyopharm, Dr Kauffman was Chief Medical Officer of Onyx Pharmaceuticals Inc., which acquired Proteolix Inc. and, before that, was President and Chief Executive Officer of EPIX Pharmaceuticals, Inc. (previously Predix Pharmaceuticals, Inc.). At Millennium Pharmaceuticals, Dr Kauffman led the development programme for Velcade®, a first-line treatment for patients with multiple myeloma. He has also held a number of senior positions at Millennium Predictive Medicine and Biogen. Dr Kauffman received his M.D. and Ph.D. from the Johns Hopkins University School of Medicine and is Board certified in Internal Medicine.

Iain Ross, Chairman of BiVictriX, commented: “We are delighted to welcome Dr Kauffman to the BiVictriX Board. He brings a wealth of expertise in oncology drug development, having been instrumental in the approval of several oncology therapeutics. We look forward to working with him to advance the development of our Bi-Cygni® therapeutics, where his proven corporate experience and extensive network will be invaluable.”